Reversal of neurodegeneration through pTau clearance by chimeric scavenger receptor monocytes
Reversal of neurodegeneration through pTau clearance by chimeric scavenger receptor monocytes
批准号:
10039698
负责人:
Michael A Curran
金额:
$44.55万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-01 至 2023-08-31
关键词:
AddressAgeAge-MonthsAlzheimer&aposs DiseaseAlzheimer&aposs disease patientAmyloid beta-ProteinAnti-Inflammatory AgentsAntibodiesAttenuatedBindingBiologyCell LineCellsCellular immunotherapyClathrinClinicalCoculture TechniquesCognitiveConfocal MicroscopyDataDegradation PathwayDendritesDeteriorationDisease ProgressionEncephalitisEndocytosisEndosomesEngineeringExposure toFeedbackFrontotemporal DementiaHippocampus (Brain)Image CytometryImpaired cognitionImpairmentIn VitroInflammationInflammation MediatorsInflammatoryInflammatory ResponseInfusion proceduresIngestionKnowledgeLysosomesMalignant NeoplasmsMeasuresMediatingMicrogliaMonoclonal AntibodiesMutateMyelogenousMyeloid CellsNerve DegenerationNeuraxisNeurodegenerative DisordersNeurofibrillary TanglesNeuronsPathologicPathologyPathway interactionsPeripheralPhagocytosisProcessProductionPropertySocietiesTauopathiesToxic effectTransgenic MiceTumor Immunitybafilomycin Abasecytokinecytotoxicitydesignextracellularglobal healthhigh riskhyperphosphorylated tauinhibitor/antagonistmacrophagemonocytemouse modelneuroinflammationneuron lossneuroprotectionneurotoxicneurotoxicitynovelnovel therapeuticsoverexpressionpreventreceptorreceptor internalizationresponsescaffoldscavenger receptortau Proteinstau aggregationtumoruptake
中文摘要
项目摘要/摘要
阿尔茨海默病(AD)是一种无法治愈的神经退行性疾病,在全球范围内将继续增长
随着全球社会老龄化,健康面临挑战,但我们完全缺乏能够减缓或逆转的治疗方法
疾病的发展。过度磷酸化的Tau(Ptau)缠结是AD的病理特征,与β不同-
淀粉样蛋白与临床认知功能减退高度相关。小胶质细胞主宰髓系间室
在中枢神经系统(CNS)内,但清除作为AD下降的ptau的能力有限
进步了。Ptau对这些细胞伴随分泌神经毒性促炎细胞因子的影响
摄取会加速神经退化,加速疾病进展。目前,还没有一种治疗方法可以
可以有意义地减少剧毒的ptau物种,寡聚ptau(OpTau),而不会引发这种
有害的神经炎症。因此,对一种催化opTau的新疗法的需求尚未得到满足
在不触发中枢神经系统髓系细胞释放炎性细胞因子的情况下降解。在肿瘤免疫方面,我们
已观察到清道夫受体FcγRIIb是一种由髓基质表达的抑制性受体
它通过网状蛋白介导的内吞作用内化,并可以抑制对各种肿瘤的细胞毒作用。
我们提出了一个新的概念,即清道夫受体的抗炎特性可以利用
目的:改变AD患者对opTau的髓系反应。与小胶质细胞不同,外周血单核细胞保留了
清除ptau组件,但确实分泌神经毒性促炎细胞因子。我们假设单核细胞
通过抗体重定向嵌合清道夫受体(CSR)结合和内化opTau的工程将停止
在抑制炎症的同时保护神经元免受opTau介导的神经毒性的AD进展
细胞因子的释放。我们已经成功地设计了一种外周巨噬细胞/单核细胞系来表达我们的
设计了由FcγRIIb支架和opTau单链可变片段组成的CSR结构
(ScFv)基于一种抗opTau抗体,它限制了AD小鼠模型的神经退行性变。首先,我们将
检测表达FcyRIIB CSR的单核/巨噬细胞系对opTau的摄取,并确定
内化是否依赖于吞噬作用或笼状蛋白介导的内吞作用。接下来,我们将调查
这些CSR表达细胞对opTau的降解效率,以及决定这是否
降解依赖于溶酶体。确定CSR单核细胞是否有能力保护原代
来自opTau毒性和自身炎症爆发的神经元,我们将与原代神经元共同培养
OpTau单独,与父母单核细胞,或与CSR表达单核细胞,并测量树突完整性
而不是支离破碎。最后,我们将在脑室内将CSR单核细胞注入Tau
从6个月大的p301S转基因小鼠开始,评估它们预防或推迟两者发病的能力
认知功能减退、中枢神经变性和病理性中枢神经系统炎症。虽然风险很高,但我们的
初步数据表明,这种方法有可能保护神经元免受opTau毒性。
英文摘要
PROJECT SUMMARY/ABSTRACT
Alzheimer's disease (AD) is an incurable neurodegenerative disease that will continue to grow as a global
health challenge as societies age worldwide, yet we entirely lack therapies capable of slowing or reversing
disease progression. Hyperphosphorylated Tau (pTau) tangles are pathological hallmarks of AD and, unlike β-
Amyloid, highly correlate with clinical cognitive deterioration. Microglia dominate the myeloid compartment
within the central nervous system (CNS), but have a limited capacity to clear pTau that declines as AD
progresses. Concomitant secretion of neurotoxic proinflammatory cytokines by these cells in response to pTau
uptake hastens neurodegeneration and accelerates disease progression. At present, no therapies exist which
can meaningfully diminish the highly toxic pTau species, oligomeric pTau (opTau), without triggering this
deleterious neuroinflammation. Thus, there is an unmet need for a novel therapeutic that catalyzes opTau
degradation without triggering inflammatory cytokine release from CNS myeloid cells. In tumor immunity, we
have observed that the scavenger receptor, FcγRIIb, is an inhibitory receptor expressed by the myeloid stroma
that internalizes via clathrin-mediated endocytosis and can act to dampen cytotoxicity against diverse tumors.
We propose the novel concept that the anti-inflammatory properties of scavenger receptors can be harnessed
to alter the myeloid response to opTau in AD. In contrast to microglia, peripheral monocytes retain the ability to
clear pTau assemblies, but do secrete neurotoxic proinflammatory cytokines. We hypothesize that monocytes
engineered to bind and internalize opTau via antibody-redirected chimeric scavenger receptors (CSR) will halt
the progression of AD by protecting neurons from opTau-mediated neurotoxicity while dampening inflammatory
cytokine release. We have successfully engineered a peripheral macrophage/monocyte cell line to express our
designed CSR construct which consists of an FcγRIIb scaffold and an opTau single-chain variable fragment
(ScFv) based on an anti-opTau antibody which limits neurodegeneration in AD mouse models. First, we will
measure uptake of opTau by a monocyte/macrophage cell line expressing the FcyRIIb CSR, and determine
whether internalization relies on phagocytosis or clathrin-mediated endocytosis. Next, we will investigate the
efficiency of degradation of opTau by these CSR expressing cells, as well as determine whether this
degradation is lysosome-dependent. To ascertain whether CSR monocytes are capable of protecting primary
neurons from opTau toxicity and from their own inflammatory burst, we will co-culture primary neurons with
opTau alone, with parental monocytes, or with CSR expressing monocytes and measure dendrite integrity
versus fragmentation. Finally, we will perform intra-cerebroventricular infusion of CSR monocytes into Tau
p301S transgenic mice starting at 6 months of age and assess their capacity to prevent or delay onset of both
cognitive decline, CNS neurodegeneration, and pathologic CNS inflammation. Although high risk, our
preliminary data suggests this approach has potential to protect neurons from opTau toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Breaking down tumor immune privilege through targeted hypoxia reduction
-
批准号:10202534
-
项目类别:
-
资助金额:$48.17万
-
财政年份:2020
-
负责人:Michael A Curran
-
依托单位:
Breaking down tumor immune privilege through targeted hypoxia reduction
-
批准号:10658860
-
项目类别:
-
资助金额:$47.21万
-
财政年份:2020
-
负责人:Michael A Curran
-
依托单位:
Breaking down tumor immune privilege through targeted hypoxia reduction
-
批准号:10028301
-
项目类别:
-
资助金额:$48.17万
-
财政年份:2020
-
负责人:Michael A Curran
-
依托单位:
Breaking down tumor immune privilege through targeted hypoxia reduction
-
批准号:10439648
-
项目类别:
-
资助金额:$47.21万
-
财政年份:2020
-
负责人:Michael A Curran
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
-
批准号:82505677
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.00万元
-
批准年份:2025
-
负责人:吕雨霏
-
依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
-
批准号:82574874
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2025
-
负责人:刘天华
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位: